B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Fluge, Øystein ^a   Risa, Kristin ^a   Lunde, Sigrid ^a   Alme, Kine ^a   Rekeland, Ingrid Gurvin ^a   Sapkota, Dipak ^a,b   Kristoffersen, Einar Kleboe ^a,b   Sørland, Kari ^a   Bruland, Ove ^a   Dahl, Olav ^a,b   Mella, Olav ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTENTION TO TREAT ANALYSIS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; REMISSION; SELF REPORT; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; ADOLESCENT; AGED; CLINICAL TRIAL; DRUG EFFECTS; FATIGUE SYNDROME, CHRONIC;

ADOLESCENT; ADULT; AGED; B-LYMPHOCYTES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RITUXIMAB;

EID: 84938831118     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129898     Document Type: Article

References (46)

1. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. (2003) Myalgic encephalomyelitis/ chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr 11: 7-36.
2. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, et al. (2011) Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med 9: 91. doi: 10.1186/1741-7015-9-91 PMID: 21794183
3. Albright F, Light K, Light A, Bateman L, Cannon-Albright LA (2011) Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol 11: 62. doi: 10.1186/1471-2377-11-62 PMID: 21619629
4. Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler Mde L, Leite JC, et al. (2011) The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. BMC Public Health 11: 402. doi: 10.1186/1471-2458-11-402 PMID: 21619607
5. Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W (1996) Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am J Med 101: 364-370. PMID: 8873506
6. Fluge O, Mella O (2009) Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 9: 28. doi: 10.1186/1471-2377-9-28 PMID: 19566965
7. Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS One 6: e26358. doi: 10.1371/journal.pone.0026358 PMID: 22039471
8. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953-959. PMID: 7978722
9. Loge JH, Kaasa S, Hjermstad MJ, Kvien TK (1998) Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol 51: 1069-1076. PMID: 9817124
10. Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483. PMID: 1593914
11. National Collaborating Centre for Primary Care (2007) National Institute for Health and Clinical Excellence: Guidance. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy) in Adults and Children. London: Royal College of General Practitioners (UK). PMID: 21563329
12. Jason LA, Brown A, Evans M, Sunnquist M, Newton JL (2013) Contrasting Chronic Fatigue Syndrome versus Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Fatigue 1: 168-183. PMID: 23914329
13. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, et al. (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62: 2227-2238. doi: 10.1002/art.27524 PMID: 20506254
14. Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. (2014) Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 82: 573-581. doi: 10.1212/WNL.0000000000000125 PMID: 24453078
15. Schroder A, Oernboel E, Licht RW, Sharpe M, Fink P (2012) Outcome measurement in functional somatic syndromes: SF-36 summary scores and some scales were not valid. J Clin Epidemiol 65: 30-41. doi: 10.1016/j.jclinepi.2011.03.012 PMID: 21764558
16. Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, et al. (2014) The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun 50: 67-76. doi: 10.1016/j.jaut.2013.12.002 PMID: 24365380
17. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613-620. PMID: 16447239
18. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63: 3692-3701. doi: 10.1002/art.30599 PMID: 22127692
19. Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A 107: 4658-4663. doi: 10.1073/pnas.1001074107 PMID: 20176942
20. Teng YK, Wheater G, Hogan VE, Stocks P, Levarht EW, Huizinga TW, et al. (2012) Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther 14: R57. doi: 10.1186/ar3770 PMID: 22409963
21. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54: 3612-3622. PMID: 17075806
22. Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P, et al. (2014) Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 50: 135-141. doi: 10.1016/j.jaut.2014.03.002 PMID: 24703438
23. Chang CM, Warren JL, Engels EA (2012) Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 118: 5929-5936. doi: 10.1002/cncr.27612 PMID: 22648858
24. Thieblemont C, Bertoni F, Copie-Bergman C, Ferreri AJ, Ponzoni M (2014) Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin Cancer Biol 24: 33-42. doi: 10.1016/j.semcancer.2013.11.005 PMID: 24333758
25. Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84: 223-243. PMID: 9281381
26. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29: 1-9. PMID: 17582741
27. Li H, Yu X, Liles C, Khan M, Vanderlinde-Wood M, Galloway A, et al. (2014) Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc 3: e000755. doi: 10.1161/JAHA.113.000755 PMID: 24572257
28. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, et al. (2011) Autoimmunity against the beta2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain 152: 2690-2700. doi: 10.1016/j.pain.2011.06.012 PMID: 21816540
29. Goebel A, Blaes F (2013) Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 12: 682-686. doi: 10.1016/j.autrev.2012.10.015 PMID: 23219953
30. Lewis I, Pairman J, Spickett G, Newton JL (2012) Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome. J Intern Med.
31. Bradley AS, Ford B, Bansal AS (2013) Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol 172: 73-80. doi: 10.1111/cei.12043 PMID: 23480187
32. Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, et al. (2013) The Role of Adaptive and Innate Immune Cells in Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis. Int Immunol.
33. Elfaitouri A, Herrmann B, Bolin-Wiener A, Wang Y, Gottfries CG, Zachrisson O, et al. (2013) Epitopes of microbial and human heat shock protein 60 and their recognition in myalgic encephalomyelitis. PLoS One 8: e81155. doi: 10.1371/journal.pone.0081155 PMID: 24312270
34. Maes M, Leunis JC (2014) Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 35: 577-585. PMID: 25617880
35. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. (2015) Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 1: e1400121.
36. Hornig M, Gottschalk G, Peterson DL, Knox KK, Schultz AF, Eddy ML, et al. (2015) Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry.
37. Avivi I, Stroopinsky D, Katz T (2013) Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev 27: 217-223. doi: 10.1016/j.blre.2013.07.002 PMID: 23953071
38. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, et al. (2007) Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 104: 20878-20883. PMID: 18093919
39. Wolach O, Shpilberg O, Lahav M (2012) Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 19: 32-38. doi: 10.1097/MOH.0b013e32834da987 PMID: 22080846
40. Arai Y, Yamashita K, Mizugishi K, Nishikori M, Hishizawa M, Kondo T, et al. (2014) Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology.
41. Rowe KS (1997) Double-blind randomized controlled trial to assess the efficacy of intravenous gamma-globulin for the management of chronic fatigue syndrome in adolescents. J Psychiatr Res 31: 133-147. PMID: 9201655
42. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P (2009) The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma 50: 1083-1095. doi: 10.1080/10428190902934944 PMID: 19399690
43. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. (2010) Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 960-968. doi: 10.1002/art.27314 PMID: 20131246
44. Mok CC (2013) Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 8: 87-100. doi: 10.2147/DDDT.S41645 PMID: 24403823
45. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E (2013) Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 8: e66308. doi: 10.1371/journal.pone.0066308 PMID: 23843952
46. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156-1164. doi: 10.1001/archneurol.2011.103 PMID: 21555606